Journal Article

A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3–Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate

Antonio Rivero-Juarez, Luis F. López-Cortés, Angela Camacho, Jose A. Mira, Francisco Téllez, Manuel Marquez, Dolores Merino, Juan A. Pineda and Antonio Rivero

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 58, issue 1, pages 130-133
Published in print January 2014 | ISSN: 1058-4838
Published online September 2013 | e-ISSN: 1537-6591 | DOI: https://dx.doi.org/10.1093/cid/cit653
A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3–Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3–coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a shorter course of peg-IFN/RBV therapy may be sufficient in this population.

Keywords: HIV; HCV; genotype 3; RVR; 24 weeks

Journal Article.  2063 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or purchase to access all content.